Alkem Laboratories Limited

Revenue ₹3,737 Cr (+10.7% YoY)

Alkem Laboratories reported Q3 FY26 revenue of ₹3,737 crore (+10.7% YoY) and EBITDA of ₹828 crore (+9% YoY), with EBITDA margin at 22.2%.

Revenue ₹4,001 Cr (+17.2% YoY)

Alkem delivered a strong Q2 FY26 with revenue of INR 4,001 crore (+17.2% YoY), EBITDA of INR 921 crore (+22.3% YoY), and PAT of INR 765 crore (+11.1% YoY).

Revenue ₹3,371 Cr (+11.2% YoY)

Alkem Laboratories reported a strong Q1 FY26 with revenue of INR 3,371 crore (+11.2% YoY) and EBITDA of INR 739 crore (+21.4% YoY), driven by robust domestic growth (1...

Revenue ₹3,144 Cr (+7.1% YoY)

Alkem Laboratories reported Q4 FY25 revenue of INR 3,144 crore, up 7.1% YoY, driven by domestic growth of 8.1% and international growth of 7.2%.

Revenue ₹3,374 Cr (+1.5% YoY)

Alkem reported Q3 FY25 revenue of INR 3,374 crore (+1.5% YoY) and EBITDA margin of 22.5% (+7.3% YoY), driven by cost optimization and focus on higher-margin offerings.

Revenue pending filing verification

Alkem's Q2 FY25 PAT grew 11% YoY to INR 6,886 million, driven by cost controls and a favorable product mix.

Revenue pending filing verification

Alkem Laboratories reported a strong Q1 FY25 with EBITDA margin expanding 700 bps YoY to 20.1%, driven by favorable API pricing, improved product mix, and cost controls.

Revenue pending filing verification

Alkem Laboratories reported Q4 FY24 PAT of INR 294 crore, impacted by a deferred tax derecognition of INR 120 crore.

Revenue pending filing verification

Alkem reported a strong Q3 FY24 with 9% YoY revenue growth and 160bps EBITDA margin expansion to 21.3%, driven by lower API costs and favorable mix shift toward higher...

Revenue pending filing verification

Alkem delivered a strong Q2 with 12% YoY revenue growth and EBITDA margin of 21.7%, well above the full-year guidance of ~16.5%.